Author Reply to “regarding Further Evidence Required to Determine Whether the Presence of Cysts Negatively Affects the Prognosis of Osteochondral Lesions of the Talus”
Xiangyun Cheng,Tong Su,Xiaoze Fan,Yuelin Hu,Chen Jiao,Qinwei Guo,Dong Jiang
DOI: https://doi.org/10.1016/j.arthro.2023.07.051
2023-01-01
Abstract:We thank Drs. Zhang, Cai, and Li for their interest in and commentary on our recently published article “Concomitant Subchondral Bone Cysts Negatively Affect Clinical Outcomes Following Arthroscopic Bone Marrow Stimulation for Osteochondral Lesions of the Talus.”1Cheng X. Su T. Fan X. Hu Y. Jiao C. Guo Q. Jiang D. Concomitant subchondral bone cysts negatively affect clinical outcomes following arthroscopic bone marrow stimulation for osteochondral lesions of the talus.Arthroscopy. 2023; 39: 2261-2262Abstract Full Text Full Text PDF PubMed Google Scholar We appreciate the opportunity to respond to their comments herein. Bone marrow stimulation (BMS) is commonly considered the first-line choice for small osteochondral lesions of the talus; however, 10% to 35% of patients still experience pain or dysfunction after BMS.2Steele J.R. Dekker T.J. Federer A.E. Liles J.L. Adams S.B. Easley M.E. Osteochondral lesions of the talus: current concepts in diagnosis and treatment.Foot Ankle Orthop. 2018; 32473011418779559Crossref Scopus (24) Google Scholar To address this issue, studying the risk factors associated with BMS is a current focus in ankle cartilage repair. Although no relevant Level I randomized controlled trials exist, a consensus meeting of specialists stated that cysts should be considered a risk factor for BMS, with 92% of experts in agreement.3Hannon C.P. Bayer S. Murawski C.D. et al.Debridement, curettage, and bone marrow stimulation: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle.Foot Ankle Int. 2018; 39: 16S-22SCrossref PubMed Scopus (62) Google Scholar Studies by Shimozono et al.,4Shimozono Y. Coale M. Yasui Y. O'Halloran A. Deyer T.W. Kennedy J.G. Subchondral bone degradation after microfracture for osteochondral lesions of the talus: An MRI analysis.Am J Sports Med. 2018; 46: 642-648Crossref PubMed Scopus (64) Google Scholar,5Shimozono Y. Dankert J.F. Deyer T.W. Mercer N.P. Kennedy J.G. Predictors of outcomes of microfracture with concentrated bone marrow aspirate for osteochondral lesions of the talus.J Cartilage Joint Preserv. 2021; 1100008Abstract Full Text Full Text PDF Scopus (3) Google Scholar Dankert et al.,6Dankert J. Kennedy J.G. Shimozono Y. Deyer T. Mercer N.P. Predictors of outcomes of microfracture for osteochondral lesions of the talus.Foot Ankle Orthop. 2022; 72473011421S2473000014Crossref Scopus (4) Google Scholar and Robinson et al.7Robinson D.E. Winson I.G. Harries W.J. Kelly A.J. Arthroscopic treatment of osteochondral lesions of the talus.J Bone Joint Surg Br. 2003; 85: 989-993Crossref PubMed Scopus (186) Google Scholar have also demonstrated the negative impact of subchondral cysts. However, this topic remains controversial, and further high-quality studies are needed to fully assess the potential impact of cystic changes.8Murawski C.D. Jamal M.S. Hurley E.T. et al.Terminology for osteochondral lesions of the ankle: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle.J ISAKOS. 2022; 7: 62-66Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar We thank Dr. Zhang for the positive evaluation, and it is worth noting that the relevant work of other international peers is also of great significance. Regarding biological products, they were not added when using BMS in this study. At present, there have been some reports of platelet-rich plasma, coagulation clots, and other biological factors promoting the repair of musculoskeletal system injury,9Danilkowicz R. Murawski C. Pellegrini M. et al.Nonoperative and operative soft-tissue and cartilage regeneration and orthopaedic biologics of the foot and ankle: An Orthoregeneration Network Foundation Review.Arthroscopy. 2022; 38: 2350-2358Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar but the effect of the biological strategy on the outcome of the osteochondral lesions of the talus remains controversial.10Johnson L.G. Buck E.H. Anastasio A.T. Abar B. Fletcher A.N. Adams S.B. The efficacy of platelet-rich plasma in osseous foot and ankle pathology: A review.Regen Med. 2023; 18: 73-84Crossref PubMed Scopus (2) Google Scholar Regarding adverse events of BMS, the recurrence rate of cysts and complications are mentioned in this article: “There were 11 patients (11/35, 31.42%; no postoperative [magnetic resonance imaging] MRI in two cystic patients) with obvious cyst recurrence in the MRI images ≥ 2 years, and one case was shown in Figure 3. Thirteen patients (13/37,35.14%) with preoperative cystic lesions showed inferior symptom relief at the latest follow-up.” As for complications, a significant difference in inversion-eversion restriction (6.7% vs 25.7%, P =.031) was observed: “There was a significant difference in inversion-eversion restriction (6.7% vs 25.7%, P = .031); no significant difference was found for sprain recurrence (11.1% vs 13.5%, P = .748) and sensory disturbance (6.7% vs 5.4%, P = .812) between the non-cyst and cyst groups.” Furthermore, there was no significant difference in reoperation rates between the cyst group and non-cyst group (4/37 vs 1/45, P = .169). In terms of functional scoring, although no significant difference was found in The American Orthopedic Foot and Ankle Scores, there is a noticeable trend toward inferior clinical outcomes in the cyst group. When considering other indicators mentioned in this article, it becomes evident that cysts have a negative impact on clinical results. We agree with the suggestion to evaluate cartilage and subchondral bone features, such as the extent of regenerated cartilage. Considering that not all the postoperative MRI scans were obtained (35 of 37 patients in the cyst group and 31 of 45 patients in the non-cyst group), the results of objective evaluation were not presented in the article. Based on the available MRI data, a significantly lower Mocart score in the cyst group compared to that in the non-cyst group was found (80.36 ± 10.36 vs 90.58 ± 10.80, P = .001), indicating a relatively poor quality of articular cartilage repair tissue in the cyst group. For the proportion of patients with bone marrow edema (BME), significant difference was found between the cyst group and non-cyst group both before surgery and at the follow-up (P < .05). Regarding patients with BME after BMS, the BME volume in the cyst group was significantly higher than that in the non-cyst group (P = .037). Finally, we once again thank your valuable insights. Considering the complexity of intra-articular abnormalities, further research is still needed focusing on the number, location, and shape of the cysts, even if the potential impact of cysts has been clarified in the present study. Download .pdf (.72 MB) Help with pdf files ICMJE author disclosure forms Regarding Further Evidence Required To Determine Whether the Presence of Cysts Negatively Affects the Prognosis of Osteochondral Lesions of the TalusArthroscopyVol. 39Issue 11PreviewBone marrow stimulation (BMS) is one of the primary treatment options for small osteochondral lesions of the talus (OLTs). The initial impression of OLTs with subchondral cysts is often negative, but the evidence supporting its detrimental effect on the efficacy of specific surgical procedure is limited compared to cases without subchondral cysts. Functional scoring is a valuable tool for assessing postoperative outcomes; however, disregarding the occurrence of adverse events poses a significant risk of drawing conclusive results. Full-Text PDF